drugset / Trial / NCT00038597
Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this research is to see if giving the drug SCH66336 by mouth can improve the disease in patients with chronic or accelerated phase CML. The safety of this treatment will also be studied.
Timeline
- Start
- 2001-04-30
- Primary completion
- 2004-05-07
- Completion
- 2004-05-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lonafarnib | Small molecule | — | Oral |